Nuvation Bio Inc. (NUVB) Price Target Lowered as IBTROZI Sales Meet Expectations
TheFly reported on January 12 that H.C. Wainwright reduced its price target on NUVB to $17 from $18 while maintaining a Buy rating.
Nuvation Bio Inc. (NUVB)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Decheng Capital Min Cui | 25,954,439 | $96,031,424 | 16.75% | |
| 2. | Laurion Capital Management Benjamin A. Smith | 9,705,532 | $35,910,468 | -6% | 0.62% |
| 3. | Millennium Management Israel Englander | 4,852,218 | $17,953,207 | -10% | 0.01% |
| 4. | Tang Capital Management Kevin C. Tang | 4,200,000 | $15,540,000 | +8% | 0.6% |
| 5. | Abrams Capital Management David Abrams | 3,811,513 | $14,102,598 | 0.23% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $1.71 | 10,000 | $17,100.00 | 29,591 | 2025-06-18 | Filing | |
| $1.79 | 4,000 | $7,160.00 | 9,902 | 2025-06-17 | Filing | |
| $1.84 | 3,300 | $6,055.50 | 5,902 | 2025-06-16 | Filing | |
| $1.81 | 50,000 | $90,350.00 | 81,000 | 2025-06-16 | Filing | |
| $1.80 | 24,000 | $43,200.00 | 50,000 | 2025-06-16 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $7.82 | 150,000 | $1,173,255.00 | 18,000 | 2025-12-01 | Filing | |
| $8.00 | 10,000 | $80,000.00 | 18,000 | 2025-11-26 | Filing | |
| $7.50 | 10,000 | $75,000.00 | 18,000 | 2025-11-25 | Filing | |
| $7.23 | 300,000 | $2,168,100.00 | 0 | 2025-11-20 | Filing | |
| $7.23 | 69,051 | $499,031.58 | 0 | 2025-11-20 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 1,588,854 | $14,236,132 | 3.43% | |
| 2. | 445,279 | $3,989,700 | 0.14% | |
| 3. | 243,848 | $2,184,878 | 0.17% | |
| 4. | 163,756 | $1,467,254 | 0.36% | |
| 5. | 126,472 | $1,133,189 | 0.06% |
News See All
Top 10 Oncology Stocks to Buy Now
The oncology market in the United States was estimated at $81.34 billion in 2025 and is expected to reach $211.78 billion by 2034 with a compound annual growth rate of 11.75%.
10 Stocks Under $10 with High Potential
On January 17, Ryan Detrick from Carson Group appeared on a CNBC Television interview to discuss the current market situation and future outlook.
Nuvation Bio Inc. (NUVB) Announces Exclusive Licensing Agreement With Eisai to Expand Global Reach of Taletrectinib
Nuvation Bio Inc. (NYSE:NUVB) is among the 14 best booming stocks to buy right now.
14 Best Booming Stocks to Buy Right Now
In a report released on January 9, Goldman Sachs said that it expects the index to rally 12% in 2026.
Nuvation Bio (NUVB) Bounces Back 12% on Impressive Clinical Trial Result
“The results published in the journal of Neuro-Oncology demonstrate Safusidenib’s impressive response rate and prolonged progression-free survival that suggest the possibility to delay chemoradiation...
Nuvation Bio (NUVB) Jumps to 3-Year High on Bullish Coverage
In its first coverage for Nuvation Bio Inc. (NYSE:NUVB), B.
Nuvation Bio Inc. (NUVB) is a Buy at H.C. Wainwright on Cancer Drug Development Progress
Nuvation Bio Inc. (NYSE:NUVB) is a must-buy penny stock to buy now. On November 4, H.C. Wainwright analyst Robert Burns reiterated a Buy rating on the stock and set a $10 price target.
11 Must-Buy Penny Stocks to Buy Now
Markets have continued to rally, with the S&P 500 already up by about 15% for the year.
12 Best American Penny Stocks to Buy Right Now
The S&P 500 is set to outperform the Russell 2000 in annual performance for the 10th time over the past 12 years.
Hedge Fund Resource Center Billionaire Hedge Funds
